Cardiolipin remodelling in mitochondrial therapeutics: translational evidence chains from elamipretide to emerging strategies
Mitochondrial therapeutics have repeatedly fallen short of disease modification, in part because inner-membrane architecture constrains both molecular access and the reversibility of bioenergetic failure. Cardiolipin (CL), the signature phospholipid of the inner mitochondrial membrane, provides a me...
Spremljeno u:
| Glavni autori: | , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2026-05-01
|
| Serija: | Frontiers in Physiology |
| Teme: | |
| Online pristup: | https://www.frontiersin.org/articles/10.3389/fphys.2026.1813119/full |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|